Thus, even if a precise definition of which specific miRNAs impact on the NRF2-ARE signature in the different types of RCC is lacking, multiple lines of evidence suggest that they can play a crucial role in supporting NRF2 aberrant activation in cancer. Here, NFE2L2 is linked to cancer.